Biosimilars bleiben in der MS-Therapie die Ausnahme
Crossref DOI link: https://doi.org/10.1007/s15005-018-2813-5
Published Online: 2018-11-23
Published Print: 2018-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Müller, Thomas
Text and Data Mining valid from 2018-11-01
Article History
First Online: 23 November 2018